Purpose Renal transplant recipients are susceptible to wound complications which can contribute to increased morbidity, re-operation rates as well as increased length of hospitalisation. Negative pressure wound therapy (NPWT) such as the Prevena have been used in complex infected and dehisced wounds in renal transplant recipients. The objective of this study is to determine if the Prevena reduces wound complications at the closed surgical site following renal transplant, when compared to standard hydrocolloid dressings. Methodology This was a multicentre, partially blinded randomised controlled trial that was performed from January 2020 to December 2023. Patients undergoing a renal transplant at these centres were allocated to one of two treatment arms, where either a Prevena device or standard hydrocolloid dressings was applied to the closed incision. Monitoring occurred during hospitalisation and up to 30 days postoperatively to review any wound complications using the ASEPSIS score. Patients were followed up to a total of 90 days. Results A total of 298 patients were included across 3 sites in Australia. 151 patients received Prevena and 147 patients received standard dressings. The wound complication rates at day 30 for the Prevena group were 23.2% (35/151) and the standard group were 24.5% (36/147). There was no significant difference between the two groups complication rates (p=0.79, OR 0.930 95%CI = 0.546 – 1.585). Conclusion In this randomised controlled trial, the Prevena did not show any improvement in wound complication rates over standard hydrocolloid dressings in renal transplant recipients. However, it is relatively safe with minimal adverse events reported.